NGNE
HOLD / NEUTRALMeanRevComposite
36.30
Technical
79.00
Fundamental
22.10
Rank
—
Price
36.55
Hurst
0.28
As of
Aug 11, 2026
Daily
Neurogene Inc.
HealthcareBiotechnologyNeurogene Inc. is a clinical-stage biotech firm focused on creating genetic treatments for uncommon neurological conditions. The company's pipeline includes NGN-401, a gene therapy in early-stage trials for Rett syndrome, and NGN-101, another investigational therapy currently being tested for CLN5 Batten disease. Founded in 2018 and based in New York, the company operates through partnerships with academic institutions and specialized research providers.
Market cap
$551.3M
P/E (trailing)
—
P/E (forward)
-4.81
PEG ratio
—
Dividend yield
0.00%
Beta
2.09
52w range
15.93 – 43.66
Return on equity
-45.31%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 27.55 (-19.6%) · range 16.37–42.84
Cycle position
39/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 41 · WEAK SETUP · exit proximity 0
Conviction
27/ 100 · maturity 0%
Buildup.3314
EMA entry setup.4241
Fundamentals.2522
Volume profile
POC
32.13
Price vs POC
-14.3%
Overhead supply
75%
Runway
+15.0%
Value area 27.83–40.04 · 75% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +5.81% | +14.08% | mature |
| 40d | -27.74% | +14.08% | mature |